Application of circulating tumor DNA in prospective clinical oncology trials-standardization of preanalytical conditions

Molecular Oncology

Volumn 11, Issue 3, 2017, Pages 295-304

  Van Dessel, Lisanne F ^a   Beije, Nick ^a   Helmijr, Jean C A ^a   Vitale, Silvia R ^a   Kraan, Jaco ^a   Look, Maxime P ^a   De Wit, Ronald ^a   Sleijfer, Stefan ^a   Jansen, Maurice P H M ^a   Martens, John W M ^a   Lolkema, Martijn P ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Blood collection tube; Cell free DNA; Circulating tumor DNA; DNA contamination; Preanalytical condition

Indexed keywords

DNA; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; EDETIC ACID;

BLOOD; BLOOD SAMPLING; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; GENOTYPING TECHNIQUE; HUMAN; ISOLATION AND PURIFICATION; NEOPLASM; POLYMERASE CHAIN REACTION; PROCEDURES; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD SPECIMEN COLLECTION; CLINICAL TRIALS AS TOPIC; DNA, NEOPLASM; EDETIC ACID; GENOTYPING TECHNIQUES; HUMANS; INDICATORS AND REAGENTS; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 85027881796     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12037     Document Type: Article

References (20)

1. Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I et al. (2014) Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 134, 1207-1213.
2. Bortner CD, Oldenburg NB and Cidlowski JA (1995) The role of DNA fragmentation in apoptosis. Trends Cell Biol 5, 21-26.
3. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199-1209.
4. Diaz LA Jr. and Bardelli A (2014) Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32, 579-586.
5. Diehl F, Li M, Dressman D, He YP, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102, 16368-16373.
6. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990.
7. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y and Vadgama JV (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14, 18925-18958.
8. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4, 136ra168.
9. Holdhoff M, Schmidt K, Donehower R and Diaz LA Jr. (2009) Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst 101, 1284-1285.
10. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R (2001) DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659-1665.
11. Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M (2016) Comparative analysis of circulating tumor DNA stability In KEDTA, Streck, and CellSave blood collection tubes. Clin Biochem 49, 1321-1330.
12. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM and Hjelm NM (1998) Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 62, 768-775.
13. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al. (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112.
14. Norton SE, Lechner JM, Williams T and Fernando MR (2013) A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 46, 1561-1565.
15. Rothwell DG, Smith N, Morris D, Leong HS, Li Y, Hollebecque A, Ayub M, Carter L, Antonello J, Franklin L et al. (2016) Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol 10, 566-574.
16. Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M and Kohlmann A (2016) Optimised PreAnalytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PLoS One 11, e0150197.
17. Shinozaki M, O’Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ and Hoon DS (2007) Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 13, 2068-2074.
18. Thermo Fisher Scientific 2016. QuantStudio 3D rare mutation analysis solution. Applied Biosystems, pp. 4.
19. Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY et al. (2015) Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem 48, 993-998.
20. Xue X, Teare MD, Holen I, Zhu YM and Woll PJ (2009) Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta 404, 100-104.